| Arthritis, Psoriatic

Stelara vs Xeljanz

Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.

Deep comparison between: Stelara vs Xeljanz with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsXeljanz has a higher rate of injection site reactions vs Stelara based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Xeljanz but not Stelara, including UnitedHealthcare

Category

Stelara

Xeljanz

At A Glance

RouteSC injection

FrequencyEvery 8-12 weeks

ClassIL-12/23 antagonist

RouteOral

FrequencyTwice daily

ClassJAK inhibitor

Indications

Psoriasis vulgaris
Arthritis, Psoriatic
Crohn Disease
Ulcerative Colitis

Rheumatoid Arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Ulcerative Colitis
Juvenile polyarthritis

Dosing

Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.

Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.

Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 5 mg twice daily (XELJANZ) or 11 mg once daily (XELJANZ XR).

Ulcerative Colitis Induction: 10 mg twice daily or 22 mg once daily for at least 8 weeks (up to 16 weeks); maintenance: 5 mg twice daily or 11 mg once daily.

Juvenile polyarthritis Weight-based dosing in pediatric patients >=2 years weighing >=10 kg; patients >=40 kg: 5 mg twice daily.

Contraindications

Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA

—

Drug Interactions

969View drug interactions

1069View drug interactions

Adverse Reactions

Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression

Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia

Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis

Most common (>=2%) Upper respiratory tract infection, nasopharyngitis, diarrhea, headache, hypertension.

Serious Serious infections (pneumonia, cellulitis, herpes zoster, urinary tract infection), malignancy, thrombosis, major adverse cardiovascular events, gastrointestinal perforations.

Postmarketing Drug hypersensitivity (angioedema, urticaria), acne.

Pharmacology

Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.

Tofacitinib is a JAK inhibitor that blocks JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 signaling, preventing phosphorylation and activation of STATs to modulate immune cell function and hematopoiesis.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Stelara